Telomere Replication Stress Induced by POT1 Inactivation Accelerates Tumorigenesis
Open accessThe DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
Genome sequencing studies have revealed a number of cancer-associated mutations in the telomere-binding factor POT1. Here, we show that when combined with p53 deficiency, depletion of murine POT1a in common lymphoid progenitor cells fosters genetic instability, accelerates the onset, and increases the severity of T cell lymphomas. In parallel, we examined human and mouse cells carrying POT1 mutations found in cutaneous T cell lymphoma (CTCL) patients. Inhibition of POT1 activates ATR-dependent DNA damage signaling and induces telomere fragility, replication fork stalling, and telomere elongation. Our data suggest that these phenotypes are linked to impaired CST (CTC1-STN1-TEN1) function at telomeres. Lastly, we show that proliferation of cancer cells lacking POT1 is enabled by the attenuation of the ATR kinase pathway. These results uncover a role for defective telomere replication during tumorigenesis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Shelterin: the protein complex that shapes and safeguards human telomeres
de Lange, T. (2005) · Genes & Development · doi:10.1101/gad.1346005 · Cited by 3,056 · cited 1×
“POT1 is a member of the six subunit shelterin complex that also comprises TRF1, TRF2, TPP1, TIN2, and RAP1 (de Lange, 2005).”
Liu, Q., Guntuku, S., Cui, X.-S., Matsuoka, S., Cortez, D., Tamai, K., Luo, G., Carattini-Rivera, S., DeMayo, F., Bradley, A., et al. (2000) · Genes & Development · doi:10.1101/gad.14.12.1448 · Cited by 1,625
DNA Damage Foci at Dysfunctional Telomeres
Takai, H., Smogorzewska, A., & de Lange, T. (2003) · Current Biology · doi:10.1016/s0960-9822(03)00542-6 · Cited by 1,409
Evolution and impact of subclonal mutations in chronic lymphocytic leukemia
Landau, D. A., Carter, S. L., Stojanov, P., McKenna, A., Stevenson, K., Lawrence, M. S., Sougnez, C., Stewart, C., Sivachenko, A., Wang, L., et al. (2013) · Cell · doi:10.1016/j.cell.2013.01.019 · Cited by 1,379
Pot1, the Putative Telomere End-Binding Protein in Fission Yeast and Humans
Baumann, P., & Cech, T. R. (2001) · Science · doi:10.1126/science.1060036 · Cited by 1,028
Mammalian Telomeres Resemble Fragile Sites and Require TRF1 for Efficient Replication
Sfeir, A., Kosiyatrakul, S. T., Hockemeyer, D., MacRae, S. L., Karlseder, J., Schildkraut, C. L., & de Lange, T. (2009) · Cell · doi:10.1016/j.cell.2009.06.021 · Cited by 990
Self-citationATR disruption leads to chromosomal fragmentation and early embryonic lethality
Brown, E. J., & Baltimore, D. (2000) · Genes & Development · doi:10.1101/gad.14.4.397 · Cited by 951 · cited 1×
“Consistent with this idea, ATR or Chk1 heterozygous mice show increased incidence of tumors (Brown and Baltimore, 2000; Liu et al., 2000; Tho et al., 2012).”
BackgroundMarino, S., Vooijs, M., van der Gulden, H., Jonkers, J., & Berns, A. (2000) · Genes & Development · doi:10.1101/gad.14.8.994 · Cited by 920
Telomere dysfunction and evolution of intestinal carcinoma in mice and humans
Rudolph, K. L., Millard, M., Bosenberg, M. W., & DePinho, R. A. (2001) · Nature Genetics · doi:10.1038/88871 · Cited by 527 · cited 2×
“Additional evidence in support of this paradigm emerged from the analysis of telomere dynamics in human tumors (Chin et al., 2004; Gordon et al., 2003; Rudolph et al., 2001) and the detection of telomeric fusions in several types of cancers (Lin et al., 2010; Simpson et al., 2015).”
BackgroundYe, J. Z.-S., Hockemeyer, D., Krutchinsky, A. N., Loayza, D., Hooper, S. M., Chait, B. T., & de Lange, T. (2004) · Genes & Development · doi:10.1101/gad.1215404 · Cited by 459
PTOP interacts with POT1 and regulates its localization to telomeres
Liu, D., Safari, A., O'Connor, M. S., Chan, D. W., Laegeler, A., Qin, J., & Songyang, Z. (2004) · Nature Cell Biology · doi:10.1038/ncb1142 · Cited by 450
Wu, L., Multani, A. S., He, H., Cosme-Blanco, W., Deng, Y., Deng, J. M., Bachilo, O., Pathak, S., Tahara, H., Bailey, S. M., et al. (2006) · Cell · doi:10.1016/j.cell.2006.05.037 · Cited by 422
POT1 loss-of-function variants predispose to familial melanoma
Robles-Espinoza, C. D., Harland, M., Ramsay, A. J., Aoude, L. G., Quesada, V., Ding, Z., Pooley, K. A., Pritchard, A. L., Tiffen, J. C., Petljak, M., et al. (2014) · Nature Genetics · doi:10.1038/ng.2947 · Cited by 391 · cited 6×
“…of telomeres 1 (POT1) have been reported in chronic lymphocytic leukemia (CLL) (Quesada et al., 2011; Ramsay et al., 2013), familial melanoma (Robles-Espinoza et al., 2014; Shi et al., 2014), cardiac angiosarcoma (Calvete et al., 2015), glioma (Bainbridge et al., 2014), mantle cell lymphoma…”
BackgroundInfluentialSelf-citationIn situ analyses of genome instability in breast cancer
Chin, K., de Solorzano, C. O., Knowles, D., Jones, A., Chou, W., Rodriguez, E. G., Kuo, W.-L., Ljung, B.-M., Chew, K., Myambo, K., et al. (2004) · Nature Genetics · doi:10.1038/ng1409 · Cited by 361 · cited 2×
“Additional evidence in support of this paradigm emerged from the analysis of telomere dynamics in human tumors (Chin et al., 2004; Gordon et al., 2003; Rudolph et al., 2001) and the detection of telomeric fusions in several types of cancers (Lin et al., 2010; Simpson et al., 2015).”
BackgroundRare missense variants in POT1 predispose to familial cutaneous malignant melanoma
NCI DCEG Cancer Sequencing Working Group, Shi, J., Laboratory, N. D. C. G. R., French Familial Melanoma Study Group, Yang, X. R., Ballew, B., Rotunno, M., Calista, D., Fargnoli, M. C., Ghiorzo, P., et al. (2014) · Nature Genetics · doi:10.1038/ng.2941 · Cited by 331
Walne, A. J., Vulliamy, T., Beswick, R., Kirwan, M., & Dokal, I. (2008) · Blood · doi:10.1182/blood-2008-05-153445 · Cited by 317 · cited 4×
“POT1 is anchored to telomeres by forming a heterodimer with TPP1, which is in turn tethered to the rest of the shelterin complex by TIN2 (Liu et al., 2004; Ye et al., 2004).”
BackgroundInfluentialHockemeyer, D., Sfeir, A. J., Shay, J. W., Wright, W. E., & de Lange, T. (2005) · The EMBO Journal · doi:10.1038/sj.emboj.7600733 · Cited by 314 · cited 5×
“Our results indicate that attenuation of the ATR-dependent DDR represents one mechanism that allows tumor cells to bypass the proliferation defect imposed by POT1 inhibition (Hockemeyer et al., 2005, 2006).”
BackgroundResultInfluentialSelf-citationDing, Z., Wu, C.-J., Jaskelioff, M., Ivanova, E., Kost-Alimova, M., Protopopov, A., Chu, G. C., Wang, G., Lu, X., Labrot, E. S., et al. (2012) · Cell · doi:10.1016/j.cell.2012.01.039 · Cited by 220 · cited 1×
“This model has been validated in vivo using a mouse model in which telomerase activity can be experimentally re-activated (Ding et al., 2012).”
MethodLin, T. T., Letsolo, B. T., Jones, R. E., Rowson, J., Pratt, G., Hewamana, S., Fegan, C., Pepper, C., & Baird, D. M. (2010) · Blood · doi:10.1182/blood-2010-02-272104 · Cited by 178 · cited 2×
“Additional evidence in support of this paradigm emerged from the analysis of telomere dynamics in human tumors (Chin et al., 2004; Gordon et al., 2003; Rudolph et al., 2001) and the detection of telomeric fusions in several types of cancers (Lin et al., 2010; Simpson et al., 2015).”
BackgroundGong, Y., & de Lange, T. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.10.016 · Cited by 102
Telomere fusion threshold identifies a poor prognostic subset of breast cancer patients
Simpson, K., Jones, R. E., Grimstead, J. W., Hills, R., Pepper, C., & Baird, D. M. (2015) · Molecular Oncology · doi:10.1016/j.molonc.2015.02.003 · Cited by 46
Cited by
Shelterin-Mediated Telomere Protection
de Lange, T. (2018) · Annual Review of Genetics · doi:10.1146/annurev-genet-032918-021921 · Cited by 816
Telomeres in cancer: tumour suppression and genome instability
Maciejowski, J., & de Lange, T. (2017) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm.2016.171 · Cited by 745
Telomere-driven diseases and telomere-targeting therapies
Martínez, P., & Blasco, M. A. (2017) · Journal of Cell Biology · doi:10.1083/jcb.201610111 · Cited by 257
“Attenuation of the ATR kinase pathway allows cancer cells lacking POT1 to proliferate, suggesting that POT1-mediated tumorigenesis may be accompanied by concomitant compensatory mechanisms that down-regulate the ATR-dependent DDR (Pinzaru et al., 2016).”
BackgroundInfluentialGlousker, G., Briod, A., Quadroni, M., & Lingner, J. (2020) · The EMBO Journal · doi:10.15252/embj.2020104500 · Cited by 51
Telomere dynamics and oxidative stress in Arabidopsis grown in lunar regolith simulant
Barcenilla, B. B., Kundel, I., Hall, E., Hilty, N., Ulianich, P., Cook, J., Turley, J., Yerram, M., Min, J.-H., Castillo-González, C., et al. (2024) · Frontiers in Plant Science · doi:10.3389/fpls.2024.1351613 · Cited by 14
Metadata
- Authors
- Pinzaru, A. M., Hom, R. A., Beal, A., Phillips, A. F., Ni, E., Cardozo, T., Nair, N., Choi, J., Wuttke, D. S., Sfeir, A., & Denchi, E. L.
- Venue
- Cell Reports
- Publisher
- Elsevier BV
- Published
- 2016-06
- Volume
- 15
- Issue
- 10
- Pages
- 2170-2184
- ISSN
- 2211-1247 (ISSN-L)
- OpenAlex
- W2407875519
- Cited by
- 114
- References
- 21
- FWCI
- 8.21
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.